OncoMatch/Clinical Trials/NCT06551584
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Is NCT06551584 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ORCA-T for acute myeloid leukemia.
Treatment: ORCA-T — The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Prior therapy
Cannot have received: allogeneic hematopoietic cell transplant
Lab requirements
Kidney function
Estimated glomerular filtration rate (eGFR) ≥ 50 mL/minute or creatinine < 2 mg/dL
Liver function
Total bilirubin < 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included once hemolysis has been excluded)
Cardiac function
Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA)
eGFR ≥ 50 mL/minute or creatinine < 2 mg/dL; Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA); DLCO (adjusted for hemoglobin) ≥ 50%; Total bilirubin < 2 times ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Palo Alto, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify